Skip to content
value.today

Alector, Inc.: peers

Change the peers

Alector, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Alector, Inc., Vogenx, Inc., SAB Biotherapeutics, Inc., Eikon Therapeutics, Inc., Agenus Inc., Fulcrum Therapeutics, Inc., Benitec Biopharma Inc., Yarrow Bioscience, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureAlector, Inc.base
ALEC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Vogenx, Inc.
VOGX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
SAB Biotherapeutics, Inc.
SABS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Eikon Therapeutics, Inc.
EIKN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Agenus Inc.
AGEN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Fulcrum Therapeutics, Inc.
FULC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Benitec Biopharma Inc.
BNTC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Yarrow Bioscience, Inc.
YARW · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$293 MOct 21, 2026 · Market data4th of 8$296 MOct 30, 2026 · Market data3rd of 8$291 MOct 30, 2026 · Market data5th of 8$290 MOct 30, 2026 · Market data6th of 8$290 MOct 22, 2026 · Market data7th of 8$283 MOct 28, 2026 · Market data8th of 8$307 MOct 29, 2026 · Market data1st of 8$307 MOct 28, 2026 · Market data2nd of 8$292 M8 ranked
Revenue (Better neither way: ranked highest first)————————$114 MFY2025 · SEC1st of 2————$1 MFY2025 · SEC2nd of 2$57 M2 ranked
Net income (Higher is better)$-143 MFY2025 · SEC6th of 6——$13 MFY2025 · SEC1st of 6——$-3 MFY2025 · SEC2nd of 6$-75 MFY2025 · SEC5th of 6$-46 MFY2026 · SEC4th of 6$-26 MFY2025 · SEC3rd of 6$-36 M6 ranked
Employees (Better neither way: ranked highest first)185As on 2021 · Profile3rd of 6——86December 31, 2025 · Profile5th of 6384December 31, 2025 · Profile2nd of 6441As on 2021 · Profile1st of 6104As on 2021 · Profile4th of 6——10December 31, 2025 · Profile6th of 61456 ranked
Growth
Market cap change, 30 days (Higher is better)————————-26.4%30 days to Oct 22, 2026 · Market dataonly one with it——————-26.4%—
Revenue growth (Higher is better)————————————————+10.4%FY2025 · SEConly one with it50th62nd————————————+10.4%—
Revenue growth, 3 years a year (Higher is better)————————————————+5.2%FY2025 · SEConly one with it42nd54th————————————+5.2%—
Margins and returns
Gross margin (Higher is better)————————————————99.1%FY2025 · SEConly one with it99th100th————————————99.1%—
Operating margin (Higher is better)————————————————-17.7%FY2025 · SEConly one with it43rd22nd————————————-17.7%—
Net margin (Higher is better)————————————————-2.7%FY2025 · SEConly one with it57th37th————————————-2.7%—
Free cash flow margin (Higher is better)————————————————-67.6%FY2025 · SEConly one with it25th10th————————————-67.6%—
Return on equity (Higher is better)-181.6%FY2025 · SEC4th of 413th5th————14.9%FY2025 · SEC1st of 487th78th————————-25.3%FY2025 · SEC2nd of 457th26th-33.2%FY2026 · SEC3rd of 452nd23rd————-29.3%4 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————21.9×price Oct 30, 2026 · Market data1st of 235th58th————9.4×price Oct 22, 2026 · Market data2nd of 213th14th————————————15.7×2 ranked
Price to sales (Better neither way: ranked highest first)————————————————2.2×price Oct 22, 2026 · Market data2nd of 235th50th————————537.8×price Oct 28, 2026 · Market data1st of 299th100th270.0×2 ranked
Price to book (Better neither way: ranked highest first)9.6×price Oct 21, 2026 · Market data1st of 483rd89th————1.9×price Oct 30, 2026 · Market data2nd of 438th46th————————0.8×price Oct 28, 2026 · Market data4th of 415th15th1.7×price Oct 29, 2026 · Market data3rd of 435th42nd————1.8×4 ranked
Free cash flow yield (Higher is better)-62.8%price Oct 21, 2026 · Market data6th of 615th6th————-15.7%price Oct 30, 2026 · Market data3rd of 637th17th————-26.7%price Oct 22, 2026 · Market data5th of 628th12th-21.4%price Oct 28, 2026 · Market data4th of 632nd14th-5.4%price Oct 29, 2026 · Market data1st of 654th26th-10.8%price Oct 28, 2026 · Market data2nd of 642nd20th-18.5%6 ranked
Financial strength
Debt to equity (Lower is better)0.3×FY2025 · SEConly one with it42nd32nd————————————————————————————0.3×—
Piotroski F-score (Higher is better)————————4 of 9FY2025 · SEConly one with it——————4.0 of 9—
Scorecard
Scorecard (Higher is better)4 of 12FY2025 · Scorecard4th of 80 of 2FY2025 · Scorecard8th of 83 of 11FY2025 · Scorecard5th of 81 of 2FY2025 · Scorecard1st of 88 of 18FY2025 · Scorecard2nd of 82 of 12FY2025 · Scorecard6th of 82 of 12FY2026 · Scorecard6th of 86 of 17FY2025 · Scorecard3rd of 830% passed8 ranked
Valuation checks (Higher is better)0 of 2FY2025 · Scorecard5th of 80 of 1FY2025 · Scorecard5th of 81 of 4FY2025 · Scorecard2nd of 80 of 1FY2025 · Scorecard5th of 83 of 5FY2025 · Scorecard1st of 81 of 4FY2025 · Scorecard2nd of 81 of 4FY2026 · Scorecard2nd of 80 of 5FY2025 · Scorecard5th of 813% passed8 ranked
Growth checks (Higher is better)1 of 2FY2025 · Scorecard2nd of 6——0 of 2FY2025 · Scorecard4th of 6——3 of 5FY2025 · Scorecard1st of 60 of 2FY2025 · Scorecard4th of 60 of 2FY2026 · Scorecard4th of 61 of 3FY2025 · Scorecard3rd of 617% passed6 ranked
Profitability checks (Higher is better)0 of 3FY2025 · Scorecard3rd of 6——1 of 3FY2025 · Scorecard2nd of 6——2 of 4FY2025 · Scorecard1st of 60 of 3FY2025 · Scorecard3rd of 60 of 3FY2026 · Scorecard3rd of 60 of 3FY2025 · Scorecard3rd of 60% passed6 ranked
Financial health checks (Higher is better)3 of 4FY2025 · Scorecard3rd of 80 of 1FY2025 · Scorecard7th of 81 of 2FY2025 · Scorecard4th of 81 of 1FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard7th of 81 of 2FY2025 · Scorecard4th of 81 of 2FY2026 · Scorecard4th of 84 of 5FY2025 · Scorecard2nd of 850% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard2nd of 5——————0 of 1FY2025 · Scorecard2nd of 50 of 1FY2025 · Scorecard2nd of 50 of 1FY2026 · Scorecard2nd of 51 of 1FY2025 · Scorecard1st of 50% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)63.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 853.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 887.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 858.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 858.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8102.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 896.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 861.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 862.8%8 ranked
Institutions holding (Better neither way: ranked highest first)1372026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 81022026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8982026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 81252026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 81512026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8912026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8492026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 81008 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+6.2 pp2026-Q2 against 2026-Q1 · 13F2nd of 6——-61.4 pp2026-Q2 against 2026-Q1 · 13F6th of 6+5.1 pp2026-Q2 against 2026-Q1 · 13F4th of 6+7.7 pp2026-Q2 against 2026-Q1 · 13F1st of 6+4.8 pp2026-Q2 against 2026-Q1 · 13F5th of 6+5.1 pp2026-Q2 against 2026-Q1 · 13F3rd of 6——+5.1 pp6 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Alector, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vogenx, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; SAB Biotherapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Eikon Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Agenus Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Fulcrum Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Benitec Biopharma Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Yarrow Bioscience, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Alector, Inc.———
Vogenx, Inc.———
SAB Biotherapeutics, Inc.———
Eikon Therapeutics, Inc.———
Agenus Inc.-17.7%FY2025
43rd percentile in Healthcaremedian -8.0%, 684 companies
22nd percentile in USAmedian 3.5%, 2,595 companies
Fulcrum Therapeutics, Inc.———
Benitec Biopharma Inc.———
Yarrow Bioscience, Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$52 M$104 M$155 M$207 M20102012201420162018202020222024Alector, Inc. $101 MSAB Biotherapeutics, Inc. $1 MAgenus Inc. $114 MFulcrum Therapeutics, Inc. $80 MBenitec Biopharma Inc. $0 MYarrow Bioscience, Inc. $1 M

Rank in the group

1st2nd3rd4th5th6th2016201720182019202020212022202320242025Alector, Inc.: 2nd of 3 in 2018Alector, Inc.: 2nd of 4 in 2019Alector, Inc.: 3rd of 6 in 2020Alector, Inc.: 1st of 5 in 2021Alector, Inc.: 1st of 6 in 2022Alector, Inc.: 2nd of 6 in 2023Alector, Inc.: 2nd of 5 in 2024Alector, Inc.SAB Biotherapeutics, Inc.: 2nd of 6 in 2020SAB Biotherapeutics, Inc.: 2nd of 5 in 2021SAB Biotherapeutics, Inc.: 3rd of 6 in 2022SAB Biotherapeutics, Inc.: 4th of 6 in 2023SAB Biotherapeutics, Inc.: 4th of 5 in 2024SAB Biotherapeutics, Inc.Agenus Inc.: 1st of 2 in 2016Agenus Inc.: 1st of 2 in 2017Agenus Inc.: 1st of 3 in 2018Agenus Inc.: 1st of 4 in 2019Agenus Inc.: 1st of 6 in 2020Agenus Inc.: 2nd of 6 in 2022Agenus Inc.: 1st of 6 in 2023Agenus Inc.: 1st of 5 in 2024Agenus Inc.: 1st of 2 in 2025Agenus Inc.Fulcrum Therapeutics, Inc.: 5th of 6 in 2020Fulcrum Therapeutics, Inc.: 3rd of 5 in 2021Fulcrum Therapeutics, Inc.: 4th of 6 in 2022Fulcrum Therapeutics, Inc.: 3rd of 6 in 2023Fulcrum Therapeutics, Inc.: 3rd of 5 in 2024Fulcrum Therapeutics, Inc.Benitec Biopharma Inc.: 3rd of 4 in 2019Benitec Biopharma Inc.: 6th of 6 in 2020Benitec Biopharma Inc.: 5th of 5 in 2021Benitec Biopharma Inc.: 6th of 6 in 2022Benitec Biopharma Inc.: 6th of 6 in 2023Benitec Biopharma Inc.Yarrow Bioscience, Inc.: 2nd of 2 in 2016Yarrow Bioscience, Inc.: 2nd of 2 in 2017Yarrow Bioscience, Inc.: 3rd of 3 in 2018Yarrow Bioscience, Inc.: 4th of 4 in 2019Yarrow Bioscience, Inc.: 4th of 6 in 2020Yarrow Bioscience, Inc.: 4th of 5 in 2021Yarrow Bioscience, Inc.: 5th of 6 in 2022Yarrow Bioscience, Inc.: 5th of 6 in 2023Yarrow Bioscience, Inc.: 5th of 5 in 2024Yarrow Bioscience, Inc.: 2nd of 2 in 2025Yarrow Bioscience, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearAlector, Inc.Vogenx, Inc.SAB Biotherapeutics, Inc.Eikon Therapeutics, Inc.Agenus Inc.Fulcrum Therapeutics, Inc.Benitec Biopharma Inc.Yarrow Bioscience, Inc.
2025————$114 MSEC1st——$1 MSEC2nd
2024$101 MSEC2nd—$1 MSEC4th—$103 MSEC1st$80 MSEC3rd—$1 MSEC5th
2023$97 MSEC2nd—$2 MSEC4th—$156 MSEC1st$3 MSEC3rd$0 MSEC6th$0 MSEC5th
2022$134 MSEC1st—$24 MSEC3rd—$98 MSEC2nd$6 MSEC4th$0 MSEC6th$0 MSEC5th
2021$207 MSEC1st—$61 MSEC2nd——$19 MSEC3rd$0 MSEC5th$1 MSEC4th
2020$21 MSEC3rd—$55 MSEC2nd—$88 MSEC1st$9 MSEC5th$0 MSEC6th$21 MSEC4th
2019$21 MSEC2nd———$150 MSEC1st—$12 MSEC3rd$0 MSEC4th
2018$28 MSEC2nd———$37 MSEC1st——$11 MSEC3rd
2017————$43 MSEC1st——$5 MSEC2nd
2016————$23 MSEC1st——$1 MSEC2nd
2015————$25 MSEC———
2014————$7 MSEC———

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Alector, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Vogenx, Inc.VOGX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $296 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $296 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • SAB Biotherapeutics, Inc.SABS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $291 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $291 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Eikon Therapeutics, Inc.EIKN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $290 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $290 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Agenus Inc.AGEN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $290 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $290 M (Oct 22, 2026) · revenue $114 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Fulcrum Therapeutics, Inc.FULC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $283 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $283 M (Oct 28, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Benitec Biopharma Inc.BNTC · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $307 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $307 M (Oct 29, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Yarrow Bioscience, Inc.YARW · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $307 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $307 M (Oct 28, 2026) · revenue $1 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Evommune, Inc.EVMN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $282 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $282 M (Oct 30, 2026) · revenue $13 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Greenwich LifeSciences, Inc.GLSI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $279 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $279 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Lyell Immunopharma, Inc.LYEL · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $278 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $278 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Prelude Therapeutics IncorporatedPRLD · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $311 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $311 M (Oct 28, 2026) · revenue $12 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Rocket Pharmaceuticals, Inc.RCKT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $274 M market cap against $293 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $274 M (Oct 28, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.